Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Takahashi K, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. Among authors: mabuchi t. J Dermatol. 2023 May;50(5):e138-e150. doi: 10.1111/1346-8138.16797. Epub 2023 Apr 1. J Dermatol. 2023. PMID: 37132187
Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010.
Akasaka E, Mabuchi T, Manabe Y, Yahagi E, Yamada-Hiruma A, Yamaoka H, Kojima T, Kato M, Ikoma N, Ozawa A, Haruki Y. Akasaka E, et al. Among authors: mabuchi t. J Dermatol. 2013 Apr;40(4):238-43. doi: 10.1111/1346-8138.12069. Epub 2013 Jan 21. J Dermatol. 2013. PMID: 23330814
Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.
Kanekura T, Seishima M, Honma M, Etou T, Eto H, Okuma K, Okubo Y, Yamaguchi Y, Kambara T, Mabuchi T, Suga Y, Morita A, Yamanishi K, Tsuruta D, Itoh K, Yamaji K, Ikeda S. Kanekura T, et al. Among authors: mabuchi t. J Dermatol. 2017 Dec;44(12):1353-1359. doi: 10.1111/1346-8138.13975. Epub 2017 Aug 3. J Dermatol. 2017. PMID: 28771892 Clinical Trial.
Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP.
Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, Ozawa A, Kanekura T, Kurosawa M, Komine M, Nakajima K, Sano S, Nemoto O, Muto M, Imai Y, Yamanishi K, Aoyama Y, Iwatsuki K; Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis. Fujita H, et al. Among authors: mabuchi t. J Dermatol. 2018 Nov;45(11):1235-1270. doi: 10.1111/1346-8138.14523. Epub 2018 Sep 19. J Dermatol. 2018. PMID: 30230572
Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
Okubo Y, Mabuchi T, Iwatsuki K, Elmaraghy H, Torisu-Itakura H, Morisaki Y, Nakajo K. Okubo Y, et al. Among authors: mabuchi t. J Eur Acad Dermatol Venereol. 2019 Feb;33(2):325-332. doi: 10.1111/jdv.15287. Epub 2018 Nov 15. J Eur Acad Dermatol Venereol. 2019. PMID: 30317671 Free PMC article. Clinical Trial.
Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
Imafuku S, Kanai Y, Murotani K, Nomura T, Ito K, Ohata C, Yamazaki F, Miyagi T, Takahashi H, Okubo Y, Saeki H, Honma M, Tada Y, Mabuchi T, Higashiyama M, Kobayashi S, Hashimoto Y, Seishima M, Kakuma T. Imafuku S, et al. Among authors: mabuchi t. J Dermatol Sci. 2021 Mar;101(3):185-193. doi: 10.1016/j.jdermsci.2021.01.002. Epub 2021 Jan 7. J Dermatol Sci. 2021. PMID: 33495058 Free article. Clinical Trial.
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Sano S, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M; Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association. Saeki H, et al. Among authors: mabuchi t. J Dermatol. 2023 Feb;50(2):e41-e68. doi: 10.1111/1346-8138.16691. Epub 2022 Dec 29. J Dermatol. 2023. PMID: 36582113
Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study.
Ohata C, Kanai Y, Murotani K, Yamazaki F, Takahashi H, Tada Y, Mabuchi T, Mizutani Y, Nomura T, Imafuku S. Ohata C, et al. Among authors: mabuchi t. Dermatol Ther (Heidelb). 2023 Apr;13(4):1039-1052. doi: 10.1007/s13555-023-00909-z. Epub 2023 Mar 6. Dermatol Ther (Heidelb). 2023. PMID: 36877438 Free PMC article.
236 results